



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

SARS-CoV-2 Virology



Yijia Li, MD^{a,b}, Jonathan Z. Li, MD, MMSc^{a,*}

KEYWORDS

- SARS-CoV-2 • COVID-19 • Viremia • Receptor-binding domain
- Monoclonal antibody

KEY POINTS

- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome is homologous to several Sarbecoviruses, but its proteins have unique features.
- SARS-CoV-2 viral evolution is more prominent in immunocompromised hosts.
- There are several variants of concern and variants of interest, with Omicron, followed by Delta variants, being the most dominant variant currently.
- Upper and lower respiratory tract SARS-CoV-2 infection follows different viral dynamics.
- Systemic dissemination serves as a marker and mechanism for COVID-19 disease severity.

INTRODUCTION

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has not ceased to wreak havoc since its identification in early 2020.^{1,2} Despite its homology with several Betacoronavirus strains including SARS-CoV-1 and bat-derived SARS-related coronaviruses (SARSr-CoVs),¹ SARS-CoV-2 owns several unique features accounting for its pathogenesis and transmission. Clinically, coronavirus disease 2019 (COVID-19) demonstrates the full spectrum of symptomatology, ranging from asymptomatic, to mild/moderately symptomatic, to critical illness with acute respiratory distress syndrome (ARDS) and death.³ In addition, presymptomatic transmission has greatly contributed to SARS-CoV-2 community spread.⁴ Asymptomatic, paucisymptomatic, and presymptomatic transmission has made it difficult to trace and contain its transmission, leading to this global pandemic that has lasted more than 2 years, with more than 330 million confirmed cases and 5.5 million reported deaths, although the attributable mortality to the COVID-19 pandemic has been estimated to be 12 to 22 million by January 2022.⁵ In this review, the authors discuss key aspects of SARS-CoV-2 virology that contribute to its variable clinical manifestations, evolution, replication dynamics in the respiratory tract, and systemic dissemination.

^a Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; ^b Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

* Corresponding author. 65 Landsdowne Street, Room 421 Cambridge, MA 02139.

E-mail address: jli@bwh.harvard.edu

Genome Structure and Viral Proteins

SARS-CoV-2 is part of the Betacoronavirus genus and Sarbecovirus subgenus. It is a single-stranded, positive-sense, 29.9-kilobase (kb) RNA virus.¹ This virus shares 96.2% identity with a bat SARSr-CoV strain RaTG13 and 79.6% with SARS-CoV-1.⁶ SARSr-CoV have also recently been recovered from pangolins (*Manis javanica*)⁷ and different species of bats (eg, RpYN06 from *Rhinolophus pusillus*⁸ in southern China and RshSTT182/RshSTT200 from *Rhinolophus shameli* in Cambodia⁹) with variable degrees of recombination detected in different regions of genome.

The SARS-CoV-2 genome consists of the following genes: open reading frame (ORF) 1a/1b, S, 3a/3b, E, M, 6, 7a/7b, 8, 9b, N, 10, with overlaps in certain regions^{1,8} (Fig. 1). The S (Spike), E (Envelope), M (Membrane), and N (Nucleocapsid) genes encode essential structural proteins, whereas the rest of the genes encode nonstructural proteins (Nsps) from ORF1a/1b and accessory factors (ORFs 3–10). Of note, ORF1a/1b encode polypeptides that are subject to viral protease-mediated cleavage into Nsp1–Nsp16.¹⁰ Nsps serve a variety of functions. For example, Nsp1 interacts with the ribosome subunit 40S and interrupts host protein translation,¹¹ whereas Nsps 7 to 10, 13 to 16 coordinate with Nsp12 to complete the replication cycle, RNA capping, and proofreads.¹² In addition, accessory factors carry additional functions necessary for immune evasion and viral replication. For example, ORF3b, 6, 7a, 8, 9b proteins have been reported to interfere with innate immune responses by antagonizing the interferon (IFN) signaling pathway.¹³ In an in vitro cell model, Lei and colleagues¹⁴ demonstrated that ORF6 protein inhibits both upstream type I IFN promoter activation and downstream IFN-stimulated gene expression. In another in vitro cell model, Xia and colleagues¹⁵ further noted that the ORF6 protein could inhibit interferon regulatory factor 3 nuclear translocation, thus blocking its binding to IFN- α/β gene promoter. In addition, ORF7a/7b and ORF3a proteins in conjunction with nsp6, nsp1, and nsp13 inhibit signal transducer and activator of transcription 1 (STAT1)/STAT2 phosphorylation or nuclear translocation, thus further blocking the type I IFN downstream signal. SARS-CoV-2 accessory proteins are also capable of antagonizing other aspects of the home immune response. For example, the ORF8 protein is capable of downregulating human leukocyte antigen-I (HLA-I) by enhancing autophagy-related HLA-I degradation,¹⁶ which may enhance escape from T-cell-mediated immunity in SARS-CoV-2 infection. Finally, many of the Nsps, accessory proteins, and structural proteins are polyfunctional. In an affinity-purification–mass spectrometry–based proteomics study, Gordan and colleagues¹⁷ reported that almost 40% of SARS-CoV-2-interacting host proteins are associated with endomembrane and vesicle trafficking/rearrangement, in addition to their previously identified functions. For example, Nsp8 participates in forming primase for RNA-dependent RNA polymerization, interaction with signal recognition particle to hijack protein translocation pathway, glycosylation, and extracellular matrix regulation; N protein, as a structural protein, also participates in RNA processing and stress granule regulation.¹⁷



Fig. 1. SARS-CoV-2 genome structure. In SARS-CoV-2 genome, ORF1a/1b encodes polypeptides that undergo viral protease-mediated cleavage to nonstructural proteins 1 to 16. Spike (S), Envelope (E), Membrane (M), and N (nucleocapsid) genes encode corresponding structural proteins. Accessory factors including ORF3a, 6, 7a, 8, and 9b contribute to viral pathogenesis and immune evasion. ORF, open reading frame; UTR, untranslated region; –1PRF, –1 programmed ribosomal frameshifting.

Of all the Nsps, Nsp12 and Nsp5 have been the primary focus of therapeutic development. Nsp12 is the RNA-dependent RNA polymerase (RdRp) that is crucial for viral replication.¹⁸ Remdesivir, an adenosine analogue inhibitor of RdRp, has been shown to shorten recovery time for hospitalized COVID-19 patients¹⁹ and has been approved by the Food and Drug Administration (FDA). Accumulating evidence has also demonstrated its efficacy in decreasing hospitalization and death in the outpatient setting.²⁰ Nsp5 is the main protease of SARS-CoV-2 (3C-like protease) and is responsible for viral polypeptide cleavage and viral maturation.²¹ Nirmatrelvir/PF-07321332²² (boosted by ritonavir), a protease inhibitor targeting 3C-like protease, has been reported to decrease the risk of hospitalization and death and has been granted Emergency Use Authorization in the outpatient setting.²³

Of all the structural proteins, Spike protein has been the center of research and therapeutic development. Spike protein consists of 2 subunits: S1 and S2. The S1 subunit contains the N-terminal domain and the receptor-binding domain (RBD) that mediate host cell binding, whereas the S2 domain is responsible for cell membrane fusion.¹ Host proteases are required to prime the Spike protein by cleavage at the boundary between S1 and S2 and the S2' site in S2 domain.²⁴ Similar to SARS-CoV-1 and SARSr-CoVs, SARS-CoV-2 binds to human angiotensin-converting enzyme 2 (ACE2) through interaction with the RBD.^{6,25} However, SARS-CoV-2 Spike protein contains a unique polybasic cleavage site at S1/s2 boundary that is recognized by Furin, an ubiquitous host protease,²⁵ which contributes to SARS-CoV-2 pathogenesis and host adaptation.^{24,26} Furin cleavage allows for the S2 subunit to mediate host cell fusion, promoting viral entry into target cells. The Spike protein is further cleaved at target cell surface by TMPRSS2 and on endocytosis, by Cathepsin L in the endosome.²⁷ Given its key role in SARS-CoV-2 lifecycle and cell entry, the Spike protein has been targeted by several monoclonal antibodies that can neutralize the virus, especially by targeting the RBD.^{28,29}

Evolution and Variants

Similar to other RNA viruses, the SARS-CoV-2 RNA-dependent RNA polymerase has a relatively high error rate, although the error rate is mitigated in part by the presence of a proofreading mechanism mediated by the nsp14-encoded exonuclease.^{12,30} There was initial optimism about the lack of genetic diversity seen in the early stages of the pandemic,³¹ including relatively limited intrahost viral diversity in next-generation sequencing studies. Lythgoe and colleagues³² demonstrate that average intrahost single-nucleotide variant (iSNV) count is 1.4 iSNVs per sample (0.47 base substitution per 10kb), and this observation was only seen at high viral loads, sampled a median of 6 days apart. In addition, the bottleneck size for intrahost variants is very small, indicating the difficulty of transmitting intrahost mutant variants to others.³² However, in immunocompromised hosts, the situation seems different. In patients with cancer infected with SARS-CoV-2, intrahost diversity is far higher than in the immunocompetent control group (iSNV 0.77 vs 0.45 base substitution per 10kb),³³ and immunocompromised individuals are at risk of persistent COVID-19 infections.³⁴ One of the most extreme cases that has been reported is an individual with antiphospholipid antibody syndrome, who was receiving a broad spectrum of immunosuppressants targeting T cells, B cells, complement system, and innate immunity. This patient suffered from persistent COVID-19 over a 5-month period and harbored constantly evolving virus and eventually succumbed to COVID-19, despite Remdesivir and monoclonal antibody administration.³⁵ Viral genome sequencing at different time points demonstrated a dynamic pattern of mutations, with an overall accumulation of mutations. When comparing sequences from approximately 5 months after the initial diagnosis, there

was an average of 4.67 base substitutions per 10kb (excluding the deletions in Spike protein region; compared with 0.45–0.47 in the aforementioned immunocompetent hosts), with mutations overrepresented in the Spike protein gene that highlights the Spike protein as the site of intense immune pressure.^{35–37} In addition, the mutations that emerged in this patient were subsequently identified as key mutations in several variants of concern, suggesting that immunosuppressed individuals may be a source for the emergence of new variants. Similar cases in immunocompromised patients infected with SARS-CoV-2 further support the negative correlation between host immunity and accelerated intrahost evolution.^{38–40}

From the population level, interhost mutations and evolution have certainly complicated this pandemic by multiple folds. D614G mutation on Spike protein was the first major mutation discovered since the beginning of this pandemic. D614G was rare before March 2020 but rapidly became the globally dominant mutation since May 2020.⁴¹ This mutation is associated with enhanced infectivity and replication compared with the original strain with D614.^{41,42} This enhanced infectivity is mediated by an increase in Furin cleavage efficiency and more frequent RBD “up” state⁴³ that characterizes a conformation facilitating ACE2 accessibility.⁴⁴ However, G614 and D614 strains have similar level of susceptibility to neutralization from convalescent plasma/serum.⁴⁵ With further global spread and replication, SARS-CoV-2 continues to diversify and has developed into multiple circulating variants. By the beginning of 2022, there have been 5 major variants of concern (VOC) and 6 variants of interest (VOI) documented on the GISAID database.^{46,47} The VOCs and certain VOIs are summarized in **Table 1**.

Among all these VOC and VOI strains, the Delta variant merits further discussion. This variant was first detected in India in December 2020 and caused a disastrous surge in COVID-19 cases and death in early 2021. By July 2021 it has already supplanted the then-dominant strains (Alpha, Beta, and Gamma) to become the dominant strain in most countries of the world.^{47,48} The Delta variant has several features that seem to enhance transmission. First, it contains several antibody evasion mutations.⁴⁹ Several neutralization studies have demonstrated that the Delta variant is associated with decreased sensitivity to convalescent sera, vaccinated sera, or bamlanivimab (a monoclonal antibody targeting the Spike protein), compared with the wild-type strains or the Alpha variant.^{50,51} In addition, real-world data demonstrate that certain adenovirus-vector-based vaccine (ChAdOx1 nCoV-19) and mRNA-based vaccine (BNT162b2) have a modestly decreased vaccine efficacy against symptomatic disease.⁴⁸ Second, the Delta variant contains certain mutations that may escape preexisting cellular immunity from prior infection or vaccination. Two groups have demonstrated that L452R, the signature mutation in the Delta variant, is associated with decrease in HLA-A24- or HLA-A02-restricted CD8+ T-cell response to the T-cell epitope containing this mutation.^{52,53} Third, the Delta variant is associated with more efficient membrane fusion independent of better ACE2 binding. Zhang and colleagues⁵⁴ demonstrated that Delta strain had higher fusion activity toward target cells in an in vitro system without having higher affinity to ACE2 compared with other variants. Last but not the least, Syed Abdullah and colleagues⁵⁵ used an SARS-CoV-2 virus-like particle model and demonstrated that key nucleocapsid mutations found in Delta variant, including R203M, are associated with enhanced viral RNA packaging and replication. Although the Beta and Gamma variants mediate a greater degree of escape against vaccine or natural immunity-mediated immune responses, the greater transmissibility of Delta allowed it to supplant these variants. Together, the features discussed earlier enable Delta variant to transmit efficiently and evade preexisting adaptive immunity, leading to higher viral shedding in the upper respiratory

Table 1
Summary of variants of concern and certain variants of interest per World Health Organization definition

Variants	First Identified	Key Spike Mutations	Impact on Antibody Neutralization	Impact on Viral Entry and Transmission
VOC				
Alpha ^a	United Kingdom	69–70del, 144del , N501Y, A570D, D614G, P681H, T716I, S982A, D1118H	+/-	++
Beta ^a	South Africa	D80A, D215G, 241–243del , K417N , E484K , N501Y, D614G, A701V	+++	++
Gamma ^a	Japan/Brazil	L18F , T20N , P26S , D138Y, R190S, K417T , E484K , <u>N501Y</u> , <u>D614G</u> , <u>H655Y</u> , T1027I, V1176F	+++	++
Delta	India	T19R , G142D, E156G, 157–158del , L452R , T478K , <u>D614G</u> , P681R, D950N	++	+++
Omicron	South Africa	A67V, del69–70, T95I, G142D, del143–145 , , del212, G339D, S371L, S373P, S375F, K417N , N440K, G446S , S477N, T478K, E484A , Q493R , G496S, Q498R , <u>N501Y</u> , Y505H, T547K, <u>D614G</u> , <u>H655Y</u> , <u>N679K</u> , <u>P681H</u> , N764K, D796Y, N856K, Q954H, N969K, L981F	++++	++++
VOI				
Lambda ^a	Peru	G75V, T76I, R246N, del247–253 , L452Q , F490S , D614G, T859N	+++	++
Iota ^a	United States	L5F, T95I, D253G , E484K , <u>D614G</u>	++	+
Mu ^a	Colombia	T95I , Y144S, Y145N, R346K, E484K , N501Y, D614G, P681H, D950N	+++	++
Kappa ^a	India	L452R , E484Q , <u>D614G</u> , <u>P681R</u> , Q1071H	+++	++

Bold font, adaptive immunity escape mutations. Underline, increase in ACE2 binding affinity and transmission.

^a Currently listed as Variant Being Monitored (VBM) by US CDC.

Data from Refs^{50,51,54,61,78,117–123}

tract,^{56,57} more rapid transmission,⁵⁸ and vaccine “breakthrough” infection⁵⁹ compared with ancestral strains. Fortunately, vaccination is still associated with more rapid viral clearance in those Delta breakthrough cases compared with unvaccinated cases.⁶⁰

The Omicron variant, first reported in South Africa in November 2021, has further led this pandemic into an uncharted water. The rate that the Omicron variant has spread world-wide has been unprecedented, and it has become the dominant strain world-wide.⁶¹ The Omicron variant has developed an extensive set of mutations in the Spike protein^{62–66}; this unfortunately leads to escape from multiple FDA-authorized monoclonal antibody treatments^{62,63} and leads to substantial reductions in vaccine-induced neutralizing titers.^{64,67,68} Somewhat reassuringly, CD4 and CD8 T cells from vaccinated and/or previously infected people retain activity against the Omicron strain,⁶⁹ although as many as 21% of the participants in one study has shown significant reduction in Omicron spike recognition by the CD8 T cells.⁷⁰ In addition, Omicron is not as efficiently antagonizing IFN signaling pathway as other variants and remain susceptible to most of the available antiviral small molecules authorized by the FDA.⁷¹ Last but not the least, several in vitro and animal studies have demonstrated that the Omicron strain preferably replicate in the upper respiratory epithelium and does not replicate well in the lungs, causing less severe inflammation in the lung tissue in animal models.^{72–74} These findings could potentially indicate differences in its clinical phenotypes and outcomes, as reported in a recent study from South Africa suggesting milder disease and lower morbidity/mortality,⁷⁵ but more evidence is needed.

Animal Reservoirs

SARS-CoV-2 seems to have broad tropism across species, and infection has been observed in a wide range of animals besides the bats.⁷⁶ Gu and colleagues⁷⁷ demonstrated that SARS-CoV-2 developed a de novo mutation in the Spike protein gene after 6 passages of a viral strain from clinical isolate in early 2020 (BetaCov/human/CHN/Beijing_IME-BJ05/2020), when VOCs/VOIs had not yet arisen. This mutation N501Y confers higher affinity to mice ACE2 and is associated with adaptation to mice⁷⁷ and is subsequently found in 4 major VOCs: Alpha, Beta, Gamma, and Omicron.^{61,78} Similarly, in domestic cats, a consensus mutation at Spike protein, H655Y, has been detected, which is also found in the Gamma and Omicron VOCs.⁷⁹ In addition, SARS-CoV-2 transmission among minks is associated with a mutation at Spike Y453F, suggesting adaptation to mink ACE2.^{80,81} A very recent study evaluating free-ranging white-tail deer in Ohio, US has demonstrated a shockingly 35.8% SARS-CoV-2 nucleic acid detection rate from nasal swabs between January and March 2021. This study further identified multiple independent human-to-deer transmission events based on the phylogenetic analysis from sequences obtained from human and deer at different locations and timepoints.⁸² Surprisingly, certain mutations that are rare in humans (<0.5%–0.05% globally) are seen in deer, including Δ 141 to 144 and E484D⁸²; this indicates a possibility of deer-to-deer transmission and independent evolution. The significance of animal reservoirs of SARS-CoV-2 remains to be determined but has important implications for our efforts to eradicate the pandemic and prevent the emergence of new variants.

Upper and Lower Respiratory Tract Infection and Replication

SARS-CoV-2 replication follows different virological dynamics in upper and lower respiratory tracts. The biological mechanism behind this finding could be due to different levels of ACE2 and entry factors expression in upper and lower airways. In an early study synthesizing multiple preexisting single-cell RNA sequencing (scRNA-seq)

datasets generated from healthy donors, Sungnak and colleagues⁸³ demonstrated that ACE2 and TMPRSS2 expression levels are higher in cells derived from nasal cavity than lungs and bronchi. This finding is further confirmed by a study using a more sensitive technique, RNA-in situ hybridization, demonstrating that upper airway epithelial cells express higher levels of ACE2 and TMPRSS2 compared with lower respiratory tract.⁸⁴ In this study, in vitro cell line models from both upper and lower respiratory tracts, and autopsy results demonstrating patchy segmental/subsegmental viral infection, further suggest that SARS-CoV-2 viral replication starts from the upper respiratory tract followed by aspiration and subsequent lower respiratory tract infection.⁸⁴ This theory is further supported by an animal model study in which only intranasal challenge was conducted in rhesus macaque.⁸⁵ In this study, an early peak of viral load in the upper respiratory system at days 2 to 6 postinfection was noted, in comparison to peak viral load at day 9 in the lower respiratory tract.⁸⁵ In a clinical cohort where the date of infection was known and only mild cases were included, Wölfel and colleagues⁸⁶ described that viral level peaked later in sputum sample compared with upper respiratory tract swab; in addition, 2 participants with lower respiratory tract involvement showed prolonged viral persistence in sputum, significant delay in viral level peak in sputum compared with the upper respiratory sample, and more than one viral level peaks in sputum.⁸⁶ These findings indicate ongoing replication in the lower respiratory tract that is disconnected from upper airway viral replication.⁸⁶ Similarly, in a cohort study of 196 hospitalized participants, the viral level from upper respiratory tract peaked within 7 days after symptom onset, whereas sputum viral level peaked between 7 and 14 days after symptom onset, highlighting the temporal and spatial gradient of SARS-CoV-2 viral spread and replication in different respiratory compartments.⁸⁷

Systemic Dissemination and Disease Severity

Plasma viremia can be detected in several respiratory viral infections including SARS-CoV-1,⁸⁸ influenza virus,⁸⁹ respiratory syncytial virus,⁹⁰ and adenovirus⁹¹ infection and has been associated with more severe disease. In contrast to SARS-CoV-1 infection, where almost 80% of patients have viremia within first 3 days of symptom onset,⁸⁸ a lower proportion of patients with COVID-19 have had detectable SARS-CoV-2 RNA in the blood,^{92–94} although rates of plasma viremia detection may be affected by disease severity, duration of symptoms, and sensitivity of the tests. The authors' group and other investigators have demonstrated that SARS-CoV-2 viremia (or referenced as RNAemia in other literature) is associated with worse disease outcomes including ARDS and death.^{92,94–97} Furthermore, those hospitalized in critical care settings have higher odds of having viremia than in noncritical care settings.^{92,95,97,98} Similarly, lower respiratory tract viral loads tend to correlate with disease severity^{97,99}; this is in stark contrast with viral levels in the upper respiratory tract, which does not seem to correlate well with severity of symptoms and disease.^{97,100–102} As discussed in the previous section, SARS-CoV-2 may have comparable replication levels in upper respiratory tract across different severity spectrum due to expression of high levels of ACE2 and other entry factors, but the determinant of severe disease is mainly due to lower respiratory tract infection and subsequent hematogenous dissemination. This hypothesis is further supported by a proteomic study showing that SARS-CoV-2 viremia is associated with severe disease and death, along with higher levels of lung damage-related proteins, fibrosis markers, and extrapulmonary organ damage markers from gastrointestinal (GI) system, and vasculature- and coagulation-related factors.⁹² Several autopsy studies have also demonstrated detection of SARS-CoV-2 RNA in multiple extrapulmonary tissues, including tissues from the GI,

cardiovascular, endocrine, lymphatic, urinary, bone marrow, reproductive, and central nervous systems.^{35,103,104} This extrapulmonary dissemination theory is further supported by mounting evidence of SARS-CoV-2 replication and virion detection in *in vitro* organoid models¹⁰⁵ and ultimately clinical samples including GI tract,^{106,107} pancreatic islets,¹⁰⁸ placenta,¹⁰⁹ kidney tissue,¹¹⁰ and endothelium.¹¹¹ However, caution is warranted when interpreting some of the transmission electron microscopy (TEM) results, as some subcellular structures can be misconstrued as virions and further clarification methods are warranted.^{112,113} In addition to extrapulmonary involvement, several studies have shown that SARS-CoV-2 viremia is further associated with complement system activation and elevated proinflammatory cytokine levels.^{92,94,98}

Given that SARS-CoV-2 infection can cause extrapulmonary involvement and dissemination from lungs, an ongoing question is the mechanism by which SARS-CoV-2 disseminates. A few studies have shown that SARS-CoV-2 virions, rather than just RNA fragments, can be detected in the blood vessels and blood. Ackermann and colleagues¹¹¹ first reported prominent endothelial injury and inflammation in COVID-19 lung autopsy compared with influenza-infected lung tissue; furthermore, SARS-CoV-2 virions are visible in endothelial cells through TEM. This result suggests that SARS-CoV-2 can infect the endovascular system, leading to systemic dissemination. From plasma samples, Jacobs and colleagues¹¹⁴ demonstrated that SARS-CoV-2 virions can be detected via TEM and further confirmed by immunostaining. These findings further support the theory that SARS-CoV-2 may first gain entry to the circulatory system from the pulmonary vasculature due to extensive lung damage, followed by infection of endothelial cells, leading to systemic dissemination of virions. However, it remains elusive whether SARS-CoV-2 virions are carried within certain cellular or acellular components in the blood during dissemination (ie, monocytes,^{115,116} platelets,¹¹⁴ and so forth) and how they infect extrapulmonary tissues.

SUMMARY

Understanding the virology behind SARS-CoV-2 infection has provided key insights into our efforts to develop antiviral agents and control the pandemic. However, there remains substantial gaps in our knowledge of SARS-CoV-2 biology and pathogenesis. Studies are needed to further dissect the functions of each nonstructural and accessory proteins and how they contribute to the pathogenesis of SARS-CoV-2. In addition, we need to understand the roles of the multiple mutations in the newly emergent variants (eg, Omicron variant) and how they contribute to increased transmission and immune evasion. There are also increasing questions on the role of systemic viral dissemination in the pathogenesis of severe disease and the detection of viremia as a prognostic marker. Furthermore, we know relatively little about the animal reservoirs of SARS-CoV-2 and their potential to fuel the emergence of new variants. The answers to these questions will be crucial as we devise improved vaccine strategies and antiviral therapies.

CLINICS CARE POINTS

- Immunocompromised patients are at higher risk of developing immune escape mutations and prolonged SARS-CoV-2 infection.
- SARS-CoV-2 has different replication dynamics in the upper and lower respiratory tracts.

- SARS-CoV-2 viremia and dissemination are associated with worse outcomes.

FUNDING SOURCES

Massachusetts Consortium for Pathogen Readiness (to J.Z. Li) and Harvard University Center for AIDS Research (NIAID 5P30AI060354 to J.Z. Li).

DISCLOSURE

J.Z.Li has consulted for Abbvie and Recovery Therapeutics.

REFERENCES

1. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet* 2020;395(10224):565–74.
2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395(10223):497–506.
3. Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. *JAMA* 2020;324(8):782–93.
4. Thompson HA, Mousa A, Dighe A, et al. SARS-CoV-2 setting-specific transmission rates: a systematic review and meta-analysis. *Clin Infect Dis* 2021;73(3):e754–64.
5. The pandemic's true death toll. 2022. Available at: <https://www.economist.com/graphic-detail/coronavirus-excess-deaths-estimates>. [Accessed 16 January 2022]. Accessed.
6. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 2020;579(7798):270–3.
7. Lam TT-Y, Jia N, Zhang Y-W, et al. Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins. *Nature* 2020;583(7815):282–5.
8. Zhou H, Ji J, Chen X, et al. Identification of novel bat coronaviruses sheds light on the evolutionary origins of SARS-CoV-2 and related viruses. *Cell* 2021;184(17):4380–91.e14.
9. Delaune D, Hul V, Karlsson EA, et al. A novel SARS-CoV-2 related coronavirus in bats from Cambodia. *Nat Commun* 2021;12(1):6563.
10. Suryawanshi RK, Koganti R, Agelidis A, et al. Dysregulation of cell signaling by SARS-CoV-2. *Trends Microbiol* 2021;29(3):224–37.
11. Thoms M, Buschauer R, Ameismeier M, et al. Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2. *Science* 2020;369(6508):1249.
12. Robson F, Khan KS, Le TK, et al. Coronavirus RNA proofreading: molecular basis and therapeutic targeting. *Mol Cell* 2020;80(6):1136–8.
13. Redondo N, Zaldívar-López S, Garrido JJ, et al. SARS-CoV-2 accessory proteins in viral pathogenesis: knowns and unknowns. *Front Immunol* 2021;12:2698.
14. Lei X, Dong X, Ma R, et al. Activation and evasion of type I interferon responses by SARS-CoV-2. *Nat Commun* 2020;11(1):3810.
15. Xia H, Cao Z, Xie X, et al. Evasion of type I interferon by SARS-CoV-2. *Cell Rep* 2020;33(1):108234.

16. Zhang Y, Chen Y, Li Y, et al. The ORF8 protein of SARS-CoV-2 mediates immune evasion through down-regulating MHC-I. *Proc Natl Acad Sci USA* 2021;118(23).
17. Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. *Nature* 2020;583(7816):459–68.
18. Hillen HS, Kocic G, Farnung L, et al. Structure of replicating SARS-CoV-2 polymerase. *Nature* 2020;584(7819):154–6.
19. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - final report. *N Engl J Med* 2020;383(19):1813–26.
20. Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. *N Engl J Med* 2022;386(4):305–15.
21. Lee J, Worrall LJ, Vuckovic M, et al. Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site. *Nat Commun* 2020;11(1):5877.
22. Owen Dafydd R, Allerton Charlotte MN, Anderson Annaliesa S, et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. *Science* 2021;eabl4784.
23. FDA. Fact sheet for healthcare providers: emergency use authorization for paxlovid. Available at: <https://www.fda.gov/media/155050/download>. [Accessed 17 January 2021]. Accessed.
24. Peacock TP, Goldhill DH, Zhou J, et al. The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets. *Nat Microbiol* 2021;6(7):899–909.
25. Walls AC, Park Y-J, Tortorici MA, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. *Cell* 2020;181(2):281–92.e286.
26. Johnson BA, Xie X, Bailey AL, et al. Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis. *Nature* 2021;591(7849):293–9.
27. Shang J, Wan Y, Luo C, et al. Cell entry mechanisms of SARS-CoV-2. *Proc Natl Acad Sci* 2020;117(21):11727.
28. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. *N Engl J Med* 2021;384(3):238–51.
29. Dougan M, Nirula A, Azizad M, et al. Bamlanivimab plus etesevimab in mild or moderate Covid-19. *N Engl J Med* 2021;385(15):1382–92.
30. Rona G, Zeke A, Miwatani-Minter B, et al. The NSP14/NSP10 RNA repair complex as a Pan-coronavirus therapeutic target. *Cell Death Differ* 2021;29(2):285–92.
31. Rausch JW, Capoferri AA, Katusiime MG, et al. Low genetic diversity may be an Achilles heel of SARS-CoV-2. *Proc Natl Acad Sci* 2020;117(40):24614.
32. Lythgoe KA, Hall M, Ferretti L, et al. SARS-CoV-2 within-host diversity and transmission. *Science* 2021;372(6539):eabg0821.
33. Siqueira JD, Goes LR, Alves BM, et al. SARS-CoV-2 genomic analyses in cancer patients reveal elevated intrahost genetic diversity. *Virus Evol* 2021;7(1):veab013.
34. Choudhary MC, Crain CR, Qiu X, et al. SARS-CoV-2 sequence characteristics of COVID-19 persistence and reinfection. *Clin Infect Dis* 2022;74(2):237–45.
35. Choi B, Choudhary MC, Regan J, et al. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. *N Engl J Med* 2020;383(23):2291–3.
36. Clark SA, Clark LE, Pan J, et al. SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms. *Cell* 2021;184(10):2605–17.e2618.

37. Starr TN, Greaney AJ, Addetia A, et al. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. *Science* 2021;371(6531):850–4.
38. Hensley MK, Bain WG, Jacobs J, et al. Intractable COVID-19 and prolonged SARS-CoV-2 replication in a CAR-T-cell therapy recipient: a case study. *Clin Infect Dis* 2021;73(3):e815–21.
39. Drouin AC, Theberge MW, Liu SY, et al. Successful clearance of 300 day SARS-CoV-2 infection in a subject with B-cell depletion associated prolonged (B-DEAP) COVID by REGEN-COV anti-spike monoclonal antibody cocktail. *Viruses* 2021;13(7):1202.
40. Gandhi S, Klein J, Robertson A, et al. De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: A case report. *medRxiv* 2021.
41. Korber B, Fischer WM, Gnanakaran S, et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. *Cell* 2020;182(4):812–27.e819.
42. Plante JA, Liu Y, Liu J, et al. Spike mutation D614G alters SARS-CoV-2 fitness. *Nature* 2021;592(7852):116–21.
43. Gobeil SMC, Janowska K, McDowell S, et al. D614G Mutation Alters SARS-CoV-2 Spike conformation and enhances protease cleavage at the S1/S2 junction. *Cell Rep* 2021;34(2):108630.
44. Cai Y, Zhang J, Xiao T, et al. Distinct conformational states of SARS-CoV-2 spike protein. *Science* 2020;369(6511):1586.
45. Li Q, Wu J, Nie J, et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. *Cell* 2020;182(5):1284–94.e1289.
46. Elbe S, Buckland-Merrett G. Data, disease and diplomacy: GISAID's innovative contribution to global health. *Glob challenges (Hoboken, NJ)* 2017;1(1):33–46.
47. GISAID. Available at: <https://www.gisaid.org/>. Accessed 01/16/2021.
48. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. *New Engl J Med* 2021;385(7):585–94.
49. Liu Z, VanBlargan LA, Bloyet LM, et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. *Cell Host Microbe* 2021;29(3):477–88.e474.
50. Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. *Nature* 2021;596(7871):276–80.
51. Edara V-V, Pinsky BA, Suthar MS, et al. Infection and vaccine-induced neutralizing-antibody responses to the SARS-CoV-2 B.1.617 variants. *New Engl J Med* 2021;385(7):664–6.
52. Zhang H, Deng S, Ren L, et al. Profiling CD8+ T Cell Epitopes of COVID-19 convalescents reveals reduced cellular immune responses to SARS-CoV-2 variants. *Cell Rep* 2021;36(11):109708.
53. Motozono C, Toyoda M, Zahradnik J, et al. SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity. *Cell Host Microbe* 2021;29(7):1124–36.e1111.
54. Zhang J, Xiao T, Cai Y, et al. Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant. *Science* 2021;374(6573):1353–60.
55. Syed Abdullah M, Taha Taha Y, Tabata T, et al. Rapid assessment of SARS-CoV-2 evolved variants using virus-like particles. *Science* 2021;374(6575):1626–32.
56. Ong SWX, Chiew CJ, Ang LW, et al. Clinical and virological features of SARS-CoV-2 variants of concern: a retrospective cohort study comparing B.1.1.7 (Alpha), B.1.315 (Beta), and B.1.617.2 (Delta). *Clin Infect Dis* 2021;ciab721.

57. Teysou E, Delagrèverie H, Visseaux B, et al. The Delta SARS-CoV-2 variant has a higher viral load than the Beta and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19. *J Infect* 2021;83(4):e1–3.
58. Liu Y, Rocklöv J. The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus. *J Travel Med* 2021; 28(7):taab124.
59. Brown CM, Vostok J, Johnson H, et al. Outbreak of SARS-CoV-2 Infections, Including COVID-19 vaccine breakthrough infections, associated with large public gatherings - barnstable county, massachusetts, July 2021. *MMWR Morb Mortal Wkly Rep* 2021;70(31):1059–62.
60. Shamier MC, Tostmann A, Bogers S, et al. Virological characteristics of SARS-CoV-2 vaccine breakthrough infections in health care workers. *medRxiv* 2021.
61. Nextstrain. Genomic epidemiology of novel coronavirus - Global subsampling. Available at: <https://nextstrain.org/ncov/gisaid/global>. Accessed 1/6/2022.
62. Cao YR, Wang J, Jian F, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. *Nature* 2021.
63. Cathcart AL, Havenar-Daughton C, Lempp FA, et al. The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. *bioRxiv* 2021.
64. Garcia-Beltran WF, St. Denis KJ, Hoelzemer A, et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. *Cell* 2022;185(3):457–66.e4.
65. Liu L, Iketani S, Guo Y, et al. Striking antibody evasion manifested by the omicron variant of SARS-CoV-2. *Nature* 2021.
66. Wilhelm A, Widera M, Grikscheit K, et al. Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and monoclonal antibodies. *medRxiv* 2021.
67. Dejnirattisai W, Shaw RH, Supasa P, et al. Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum. *Lancet* 2022; 399(10321):234–6.
68. Nemet I, Kliker L, Lustig Y, et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2 omicron infection. *N Engl J Med* 2021.
69. Liu J, Chandrashekar A, Sellers D, et al. Vaccines elicit highly cross-reactive cellular immunity to the SARS-CoV-2 omicron variant. *medRxiv* 2022.
70. Naranbhai V, Nathan A, Kaseke C, et al. T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all prior infected and vaccinated individuals. *medRxiv* 2022.
71. Bojkova D, Widera M, Ciesek S, et al. Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant SARS-CoV-2 isolates. *bioRxiv* 2022.
72. McMahan K, Giffin V, Tostanoski LH, et al. Reduced Pathogenicity of the SARS-CoV-2 Omicron Variant in Hamsters. *bioRxiv* 2022.
73. Bentley EG, Kirby A, Sharma P, et al. SARS-CoV-2 Omicron-B.1.1.529 Variant leads to less severe disease than Pango B and Delta variants strains in a mouse model of severe COVID-19. *bioRxiv* 2021.
74. Meng B, Ferreira IATM, Abdullahi A, et al. SARS-CoV-2 Omicron spike mediated immune escape, infectivity and cell-cell fusion. *bioRxiv* 2021.
75. Maslo C, Friedland R, Toubkin M, et al. Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared With Previous Waves. *JAMA* 2022;327(6):583–4.
76. Conceicao C, Thakur N, Human S, et al. The SARS-CoV-2 Spike protein has a broad tropism for mammalian ACE2 proteins. *PLOS Biol* 2020;18(12):e3001016.

77. Gu H, Chen Q, Yang G, et al. Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. *Science* 2020;369(6511):1603–7.
78. Tzou PL, Tao K, Nouhin J, et al. Coronavirus antiviral research database (CoV-RDB): an online database designed to facilitate comparisons between candidate anti-coronavirus compounds. *Viruses* 2020;12(9):1006.
79. Braun KM, Moreno GK, Halfmann PJ, et al. Transmission of SARS-CoV-2 in domestic cats imposes a narrow bottleneck. *PLoS Pathog* 2021;17(2):e1009373.
80. Oude Munnink BB, Sikkema RS, Nieuwenhuijse DF, et al. Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans. *Science* 2021;371(6525):172.
81. Bayarri-Olmos R, Rosbjerg A, Johnsen LB, et al. The SARS-CoV-2 Y453F mink variant displays a pronounced increase in ACE-2 affinity but does not challenge antibody neutralization. *J Biol Chem* 2021;296:100536.
82. Hale VL, Dennis PM, McBride DS, et al. SARS-CoV-2 infection in free-ranging white-tailed deer. *Nature* 2022;602(7897):481–6.
83. Sungnak W, Huang N, Bécavin C, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. *Nat Med* 2020;26(5):681–7.
84. Hou YJ, Okuda K, Edwards CE, et al. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. *Cell* 2020;182(2):429–46.e414.
85. Zheng H, Li H, Guo L, et al. Virulence and pathogenesis of SARS-CoV-2 infection in rhesus macaques: a nonhuman primate model of COVID-19 progression. *PLOS Pathog* 2020;16(11):e1008949.
86. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. *Nature* 2020;581(7809):465–9.
87. Regan J, Flynn JP, Rosenthal A, et al. Viral load kinetics of SARS-CoV-2 in hospitalized individuals with COVID-19. *Open Forum Infect Dis* 2021;8(8):ofab153.
88. Grant PR, Garson JA, Tedder RS, et al. Detection of SARS coronavirus in plasma by real-time RT-PCR. *N Engl J Med* 2003;349(25):2468–9.
89. Choi SM, Xie H, Campbell AP, et al. Influenza viral RNA detection in blood as a marker to predict disease severity in hematopoietic cell transplant recipients. *J Infect Dis* 2012;206(12):1872–7.
90. Waghmare A, Campbell AP, Xie H, et al. Respiratory syncytial virus lower respiratory disease in hematopoietic cell transplant recipients: viral RNA detection in blood, antiviral treatment, and clinical outcomes. *Clin Infect Dis* 2013;57(12):1731–41.
91. Taniguchi K, Yoshihara S, Tamaki H, et al. Incidence and treatment strategy for disseminated adenovirus disease after haploidentical stem cell transplantation. *Ann Hematol* 2012;91(8):1305–12.
92. Li Y, Schneider AM, Mehta A, et al. SARS-CoV-2 viremia is associated with distinct proteomic pathways and predicts COVID-19 outcomes. *J Clin Invest* 2021;131(13):e148635.
93. Prebensen C, Hre PLM, Jonassen C, et al. SARS-CoV-2 RNA in plasma is associated with ICU admission and mortality in patients hospitalized with COVID-19. *Clin Infect Dis* 2020;73(3):e799–802.
94. Gutmann C, Takov K, Burnap SA, et al. SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care. *Nat Commun* 2021;12(1):3406.
95. Chen X, Zhao B, Qu Y, et al. Detectable serum severe acute respiratory syndrome Coronavirus 2 viral load (RNAemia) is closely correlated with drastically

- elevated interleukin 6 level in critically ill patients with coronavirus disease 2019. *Clin Infect Dis* 2020;71(8):1937–42.
96. Eberhardt KA, Meyer-Schwickerath C, Heger E, et al. RNAemia corresponds to disease severity and antibody response in hospitalized COVID-19 patients. *Viruses* 2020;12(9):1045.
 97. Fajnzylber J, Regan J, Coxen K, et al. SARS-CoV-2 viral load is associated with increased disease severity and mortality. *Nat Commun* 2020;11(1):5493.
 98. Bermejo-Martin JF, González-Rivera M, Almansa R, et al. Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19. *Crit Care* 2020;24(1):691.
 99. Buetti N, Wicky P-H, Le Hingrat Q, et al. SARS-CoV-2 detection in the lower respiratory tract of invasively ventilated ARDS patients. *Crit Care* 2020;24(1):610.
 100. Lee S, Kim T, Lee E, et al. Clinical course and molecular viral shedding among asymptomatic and symptomatic patients with SARS-CoV-2 infection in a community treatment center in the republic of Korea. *JAMA Intern Med* 2020;180(11):1447–52.
 101. Ra SH, Lim JS, Kim G-u, et al. Upper respiratory viral load in asymptomatic individuals and mildly symptomatic patients with SARS-CoV-2 infection. *Thorax* 2021;76(1):61.
 102. Chew KW, Moser C, Daar ES, et al. Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19. *medRxiv* 2021.
 103. Yao X-H, Luo T, Shi Y, et al. A cohort autopsy study defines COVID-19 systemic pathogenesis. *Cell Res* 2021;31(8):836–46.
 104. Nie X, Qian L, Sun R, et al. Multi-organ proteomic landscape of COVID-19 autopsies. *Cell* 2021;184(3):775–91.e714.
 105. Lamers MM, Beumer J, van der Vaart J, et al. SARS-CoV-2 productively infects human gut enterocytes. *Science* 2020;369(6499):50–4.
 106. Qian Q, Fan L, Liu W, et al. Direct evidence of active SARS-CoV-2 replication in the intestine. *Clin Infect Dis* 2020.
 107. Das Adhikari U, Eng G, Farcasanu M, et al. Fecal SARS-CoV-2 RNA is associated with decreased COVID-19 survival. *Clin Infect Dis* 2021;ciab623.
 108. Steenblock C, Richter S, Berger I, et al. Viral infiltration of pancreatic islets in patients with COVID-19. *Nat Commun* 2021;12(1):3534.
 109. Facchetti F, Bugatti M, Drera E, et al. SARS-CoV2 vertical transmission with adverse effects on the newborn revealed through integrated immunohistochemical, electron microscopy and molecular analyses of Placenta. *EBioMedicine* 2020;59:102951.
 110. Su H, Yang M, Wan C, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. *Kidney Int* 2020;98(1):219–27.
 111. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. *N Engl J Med* 2020;383(2):120–8.
 112. Akilesh S, Nicosia RF, Alpers CE, et al. Characterizing viral infection by electron microscopy: lessons from the coronavirus disease 2019 pandemic. *Am J Pathol* 2021;191(2):222–7.
 113. Bullock HA, Goldsmith CS, Miller SE. Best practices for correctly identifying coronavirus by transmission electron microscopy. *Kidney Int* 2021;99(4):824–7.
 114. Jacobs JL, Staines B, Bain W, et al., SARS-CoV-2 Viremia is Associated with COVID-19 Severity and Predicts Clinical Outcomes, *Clin Infect Dis*, 2021; ciab686 [Online ahead of print]

115. Dias SSG, Soares VC, Ferreira AC, et al. Lipid droplets fuel SARS-CoV-2 replication and production of inflammatory mediators. *PLoS Pathog* 2020;16(12): e1009127.
116. Junqueira C, Crespo Ã, Ranjbar S, et al. SARS-CoV-2 infects blood monocytes to activate NLRP3 and AIM2 inflammasomes, pyroptosis and cytokine release. *Res Sq* 2021.
117. Baum A, Fulton BO, Wloga E, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. *Science* 2020;369(6506):1014.
118. McCarthy KR, Rennick LJ, Nambulli S, et al. Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape. *Science* 2021;371(6534): 1139.
119. Pegu A, O'Connell S, Schmidt SD, et al. Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants. *Science* 2021;373(6561): 1372–7.
120. Krause PR, Fleming TR, Longini IM, et al. SARS-CoV-2 variants and vaccines. *New Engl J Med* 2021;385(2):179–86.
121. Tada T, Zhou H, Dcosta BM, et al. SARS-CoV-2 lambda variant remains susceptible to neutralization by mRNA vaccine-elicited antibodies and convalescent serum. *bioRxiv* 2021.
122. Uriu K, Kimura I, Shirakawa K, et al. Neutralization of the SARS-CoV-2 Mu Variant by convalescent and vaccine serum. *New Engl J Med* 2021;385(25):2397–9.
123. Abdel Latif A, Mullen JL, Alkuzweny M, et al. Center for viral systems biology. Lineage Comparison *Outbreakinfo Available at: <https://outbreak.info/>*. Accessed date 1/12/2022.